Semaglutide: 10MG

£39.99

Purity: ≥ 99%

£39.99

Semaglutide: 10MG

Name: Semaglutide: 10MG
Brand: Pure Grade Labs
Price: 39.99 GBP
Availability: OutOfStock

£39.99

Purity: ≥ 99%

£39.99

METABOLIC - Visceral fat loss & body composition research

GLYCAEMIC - Insulin function & blood sugar regulation research

CARDIOVASCULAR - Heart health & cardiometabolic risk reduction research

NEUROENDOCRINE - Hunger suppression & satiety signalling research

Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), a 30-amino acid incretin hormone secreted by intestinal L-cells in response to food intake. The native GLP-1 molecule has a half-life of under two minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4) and renal clearance. Semaglutide overcomes this through two key structural modifications: a C-18 fatty diacid chain attachment at lysine-26 (via a linker) that promotes albumin binding and extends renal half-life, and a substitution at position 8 (alanine to alpha-aminoisobutyric acid) that confers resistance to DPP-4 enzymatic cleavage. The result is a half-life of approximately 165-184 hours, enabling once-weekly subcutaneous dosing.

Semaglutide is one of the most extensively studied research compounds in metabolic medicine. It has completed multiple large-scale Phase 3 clinical trial programmes - SUSTAIN (type 2 diabetes), PIONEER (oral formulation), and STEP (obesity) - involving tens of thousands of participants. The compound received FDA approval for type 2 diabetes (Ozempic, 2017), obesity management (Wegovy, 2021), and cardiovascular risk reduction (2023). It is additionally available in an oral formulation (Rybelsus). This depth of human clinical data is virtually unmatched among research peptides.

Mechanism: Full agonist at the GLP-1 receptor. Acts centrally (hypothalamic appetite regulation via arcuate nucleus) and peripherally (pancreatic insulin secretion, gastric emptying delay, glucagon suppression). Bioavailability after subcutaneous administration is approximately 89%, with peak concentration at 1-3 days post-injection.

Research Context: Evidence derived from multiple Phase 3 RCT programmes with combined enrolment of 40,000+ participants across diabetes, obesity, and cardiovascular indications. The SELECT cardiovascular outcomes trial (n=17,604) demonstrated a 20% reduction in major adverse cardiovascular events. Among the strongest evidence bases of any injectable research compound.

Key Structural Features: 34-residue GLP-1 analogue | Aib substitution at position 8 (DPP-4 resistance) | C-18 fatty diacid linker at Lys-26 (albumin binding) | Half-life ~165-184 hours

Peptide Length: 34 Amino Acids

Molecular Weight: 4,113.6 g/mol

CAS Number: 910463-68-2

Form: Lyophilised Solid

The following summaries are drawn from peer-reviewed publications. Semaglutide's evidence base includes multiple large Phase 3 RCTs and cardiovascular outcomes trials across tens of thousands of participants - among the highest-quality evidence bases for any injectable research compound. Pure Grade Labs does not interpret these findings as evidence of efficacy in humans outside of their stated research contexts.

New England Journal of Medicine: STEP 1 Trial: Once-weekly semaglutide 2.4mg produces 14.9% mean body weight reduction in adults with obesity (n=1,961)

New England Journal of Medicine (SELECT Trial): SELECT Trial: Semaglutide reduces major adverse cardiovascular events by 20% in adults with obesity and established CVD (n=17,604)

ScienceDirect / Metabolism Review: Semaglutide reduces total fat mass by 3.5% and visceral fat by 2.0% while increasing lean body mass proportion

References

https://pubmed.ncbi.nlm.nih.gov/41283266/

https://pubmed.ncbi.nlm.nih.gov/40934115/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12413075/

https://pmc.ncbi.nlm.nih.gov/articles/PMC11790292/

https://pmc.ncbi.nlm.nih.gov/articles/PMC10092086/

https://pmc.ncbi.nlm.nih.gov/articles/PMC7905697/

https://pmc.ncbi.nlm.nih.gov/articles/PMC10552354/

https://pmc.ncbi.nlm.nih.gov/articles/PMC10851954/

https://pmc.ncbi.nlm.nih.gov/articles/PMC11144277/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9807016/

Every batch of Semaglutide supplied by Pure Grade Labs is accompanied by a Certificate of Analysis (COA) from an independent third-party analytical laboratory. The COA confirms identity, purity by HPLC, and absence of contaminants. Batch-specific documentation is linked below.

Semaglutide is supplied as a lyophilised (freeze-dried) solid. This formulation maximises compound stability during transit and long-term storage. Follow the specifications below carefully to preserve peptide integrity.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow the sealed vial to reach room temperature before opening to minimise condensation and moisture introduction to the lyophilised cake.
Use bacteriostatic water (BAC water) as the reconstitution solvent. Add solvent slowly down the inside wall of the vial - do not inject directly onto the lyophilised powder.
Gently swirl the vial until fully dissolved. Do not vortex or shake vigorously. Semaglutide is a fragile peptide - rough handling degrades the molecule.
Inspect the solution: it should be clear and colourless. Discard if cloudy, discoloured, or contains particulate matter.
Once reconstituted, store at 2-8°C. Use within 28 days. Do not freeze reconstituted solution.

Semaglutide supplied by Pure Grade Labs is intended exclusively for in vitro research and laboratory use. While semaglutide is FDA-approved under the brand names Ozempic, Wegovy, and Rybelsus for specific clinical indications, the research-grade compound supplied here is not equivalent to those approved pharmaceutical products and is not approved for human administration.

This product is not a drug, medicine, or supplement and must not be used as such outside of a licensed clinical or research context.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy in humans for any use of this research compound.
Semaglutide is a prescription-only medicine in all jurisdictions where it is approved. Purchase and self-administration of semaglutide outside of a licensed prescriber relationship is subject to regulatory restrictions and may be illegal in your jurisdiction.
Semaglutide is prohibited in sport by WADA under the S4 Hormone and Metabolic Modulators category. Athletes subject to drug testing must be aware of this classification.
Known safety signals include gastrointestinal adverse events (nausea, vomiting, diarrhoea), gallbladder-related disorders, and a black box warning regarding thyroid C-cell tumour risk (based on rodent data) in individuals with a history of medullary thyroid carcinoma or MEN2.
Purchasers are solely responsible for compliance with all applicable laws and regulations in their jurisdiction.

All product information, research summaries, and study citations presented on this page are provided for informational context only and do not constitute medical advice, endorsement of any treatment, or recommendation for human use.